The National Institutes of Health is enrolling for the last of three Phase 3 clinical trials to evaluate the use of Bristol Myers Squibb and Pfizer Inc.’s Eliquis to treat blood clots in Covid-19 patients .
- Trials seeks to answer critical questions about the proper use of blood thinners or anticoagulants in treatment of Covid-19 patients, particularly those who suffer from life-threatening blood clots
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story: